Drugs / Neridronic acid
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02402530 | Apr 2015 → Aug 2016 | complex regional pain syndrome type 1 | Grünenthal GmbH | Completed | No outcome recorded |
| Phase 33 trials · 1 met primary · 1 missed | ||||||
| Phase 3 | NCT03560986 | May 2018 → Aug 2019 | complex regional pain syndrome | Grünenthal GmbH | Terminated | Missed primary Stop: Business |
| Phase 3 | NCT03530345 | May 2018 → Jul 2019 | complex regional pain syndrome | Grünenthal GmbH | Terminated | Met primary Stop: Business |
| Phase 3 | NCT02972359 | Dec 2016 → Jan 2019 | complex regional pain syndrome | Grünenthal GmbH | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neridronic acid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03530345 ↗ |
| Route | Intravenous | “Neridronic acid administered as intravenous infusion.” NCT02402530 ↗ |